CN111560335A - Bifidobacterium lactis for relieving asthma and application thereof - Google Patents
Bifidobacterium lactis for relieving asthma and application thereof Download PDFInfo
- Publication number
- CN111560335A CN111560335A CN202010460612.4A CN202010460612A CN111560335A CN 111560335 A CN111560335 A CN 111560335A CN 202010460612 A CN202010460612 A CN 202010460612A CN 111560335 A CN111560335 A CN 111560335A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium lactis
- product
- lactis probio
- relieving asthma
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
- A23C11/106—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The application provides a Bifidobacterium lactis Probio-M8 strain for relieving asthma and application thereof, wherein the Bifidobacterium lactis Probio-M8 has the effect of relieving asthma, the application comprises the step of preparing a functional health product by using the Bifidobacterium lactis Probio-M8, and the application thereofThe application of the bifidobacterium lactis Probio-M8 in relieving asthma comprises the preparation of a direct vat set starter, a probiotic solid beverage, a tablet candy and a functional medicine auxiliary material, wherein in the application of relieving asthma, the number of the viable bacteria of the bifidobacterium lactis Probio-M8 is more than or equal to 1 × 106CFU/g, and the product for relieving asthma comprises food and health food, and comprises a bean product, a dairy product or a fruit and vegetable product which is produced by using a leaven containing bifidobacterium lactis Probio-M8.
Description
Technical Field
The application relates to the technical field of microorganisms, in particular to bifidobacterium lactis for relieving asthma and application thereof.
Background
Asthma is a common respiratory disease, has the characteristic of repeated attack, is rapid in attack and is manifested by cough, chest distress and dyspnea, and the life safety can be endangered if the asthma is not treated in time. The prevalence rate of adult asthma in China is 1.24%, and the disease is better to be found in people with family history of asthma, complications, obesity, smoking, allergen exposure and the like. The prevalence of asthma is on an increasing trend year by year due to urbanization and lifestyle changes. According to WHO online death database analysis, asthma death data in the age group of 5-34 years shows that the global asthma mortality rate is 0.19/10 ten thousand.
Asthma is not easy to be cured radically, and is generally treated by adopting medicaments, and the traditional common hormone medicaments for treating asthma can relieve the illness state of patients, but bring certain side effects. For example, it may cause arrhythmia, cardiovascular adverse reaction, osteoporosis, hypertension, cataract, glaucoma, etc.
Therefore, there is a need for a product without side effects to alleviate and treat asthma.
Disclosure of Invention
The application aims to provide a Bifidobacterium lactis Probio-M8 strain for relieving asthma, wherein the Bifidobacterium lactis Probio-M8 is separated from the breast milk of a Chinese healthy woman.
The Bifidobacterium lactis Probio-M8 provided by the application is preserved in the China general microbiological culture Collection center of the China Committee for culture Collection of microorganisms 20.9.2019, the preservation number is CGMCC No.18610, the Bifidobacterium lactis is classified and named as Bifidobacterium lactis, and the preservation address is No. 3 of West Lu No.1 of Beijing Korean area in Beijing.
The Bifidobacterium lactis Probio-M8 is used for relieving asthma, and the Bifidobacterium lactis Probio-M8 can relieve asthma.
Another objective of the present application is to provide an application of bifidobacterium lactis Probio-M8 in preparing a product for relieving asthma.
Optionally, the application of bifidobacterium lactis Probio-M8 in preparing the product for relieving asthma comprises preparing a functional health product from bifidobacterium lactis Probio-M8.
Optionally, the functional health product comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and functional pharmaceutical auxiliary materials.
Optionally, the number of viable bacteria of Bifidobacterium lactis Probio-M8 in the asthma relieving product prepared from Bifidobacterium lactis Probio-M8 is not less than 1 × 106CFU/g。
The application also provides a product for relieving asthma, which contains the bifidobacterium lactis Probio-M8, and the product comprises food and health food.
Optionally, the number of viable bacteria of bifidobacterium lactis Probio-M8 in the product for relieving asthma is more than or equal to 1 × 106CFU/g。
Optionally, the product for relieving asthma further comprises a bean product, a dairy product or a fruit and vegetable product produced by using a leaven containing bifidobacterium lactis Probio-M8.
In an achievable mode, the adjuvant of the functional food for relieving asthma comprises special food for asthma and special food for the aged.
In one realizable approach, the functional pharmaceutical adjunct materials include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, tonicity adjusting agents, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integration agents, penetration enhancers, pH adjusting agents, buffers, plasticizers, surfactants, foaming agents, antifoaming agents, thickeners, encapsulation agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids, and release retardants.
In one achievable form, the asthma-relieving product further comprises an additive comprising microcrystalline cellulose, hydroxypropyl methylcellulose, and refined lecithin.
In one implementation, the asthma-relieving product further comprises a pharmaceutical product in a dosage form comprising granules, capsules, tablets, pills, or oral liquid.
The application fields comprise the clinical application field, the food field and the functional food field.
The application provides a bifidobacterium lactis Probio-M8 strain for relieving asthma and application thereof, wherein the bifidobacterium lactis Probio-M8 has the effect of relieving asthma, and is specifically represented as follows: significantly improve the clinical symptoms of asthma patients; the richness of Klebsiella pneumoniae of a patient is obviously reduced; the abundance of bifidobacteria in intestinal animals of patients is remarkably increased; significantly reducing the metabolic pathways for aldosterone synthesis and secretion in the patient. Therefore, the bifidobacterium lactis Probio-M8 can improve the cell factors in the organism by regulating the intestinal flora, achieve good immune function, effectively relieve asthma symptoms and have great prospect in preparing products for relieving asthma. The remarkable functional characteristics of the bifidobacterium lactis Probio-M8 enable the bifidobacterium lactis to be widely applied to direct vat set starter cultures, probiotic solid beverages, foods, medicines and functional medicine auxiliary materials.
Drawings
In order to more clearly explain the technical solution of the present application, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious to those skilled in the art that other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a flow chart of experimental design of the effect of Bifidobacterium lactis Probio-M8 in relieving asthma;
FIG. 2 is a graph of the effect of Bifidobacterium lactis Probio-M8 on ACT in asthmatic patients;
FIG. 3 is a graph of the effect of Bifidobacterium lactis Probio-M8 on FeNO in asthmatic patients;
FIG. 4 is a graph of the effect of Bifidobacterium lactis Probio-M8 on Klebsiella pneumoniae in asthmatics;
FIG. 5 shows the effect of Bifidobacterium lactis Probio-M8 on bifidobacteria in intestinal animals of asthmatic patients;
FIG. 6 is the analysis of the difference in the metabolic function of asthma patients after administration of Bifidobacterium lactis Probio-M8.
Detailed Description
Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings. When the following description refers to the accompanying drawings, like numbers in different drawings represent the same or similar elements unless otherwise indicated. The embodiments described in the following examples do not represent all embodiments consistent with the present application. But merely as exemplifications of systems and methods consistent with certain aspects of the application, as recited in the claims.
The probiotics can balance the flora structure of human bodies, and has the functions of promoting antigen degradation, regulating proinflammatory and anti-inflammatory factors and the like. The intestinal flora is the flora with the most quantity and the most complex structure composition in a human body, and is closely related to the establishment and the stability of immune homeostasis and the normal exertion of the functions of an immune system. The probiotics can competitively inhibit the colonization of potential pathogenic bacteria in the intestinal tract, stabilize the intestinal mucosa barrier and prevent the pathogens from entering intestinal epithelial cells. After the oral probiotics reach the intestinal tract, the probiotics can be colonized in the intestinal tract and the host intestinal flora structure can be adjusted. The intestinal microorganisms directly influence the microbial flora in the lung through immune cells and microbial metabolites flowing along with blood circulation, promote the organism to release cytokines, enhance the activity of the immune cells, participate in the metabolism of the organism, prevent the pulmonary inflammation from deteriorating, and play a role in relieving asthma.
In one aspect, the application provides a bifidobacterium lactis Probio-M8 for relieving asthma, the bifidobacterium lactis Probio-M8 can effectively relieve asthma, and the bifidobacterium lactis Probio-M8 is a probiotic strain with potential probiotic characteristics, which is selected from 540 lactic acid bacteria and bifidobacterium separated from 100 breast milk samples of Chinese healthy women and has good gastrointestinal fluid and bile salt tolerance.
The Bifidobacterium lactis Probio-M8 provided by the application is preserved in the general microbiological center of China Committee for culture Collection of microorganisms 20.9.2019, the preservation number is CGMCC No.18610, the Bifidobacterium lactis is classified and named as Bifidobacterium lactis, and the preservation address is No. 3 of West Lu No.1 of the sunward area of Beijing, institute of microbiology of China academy of sciences; the detection result of the strain is survival.
In another aspect, the application provides the use of bifidobacterium lactis Probio-M8 in the preparation of a product for relieving asthma.
The application of the bifidobacterium lactis Probio-M8 in preparing the product for relieving asthma comprises preparing a functional health product from the bifidobacterium lactis Probio-M8.
The functional health product comprises a direct vat set starter, a probiotic solid beverage, a tablet candy and a functional medicine auxiliary material.
The number of viable bacteria of the Bifidobacterium lactis Probio-M8 in the product for relieving asthma prepared from the Bifidobacterium lactis Probio-M8 is more than or equal to 1 × 106CFU/g。
The application also provides a product for relieving asthma, which contains the bifidobacterium lactis Probio-M8, and the product comprises food and health food.
The number of viable bacteria of the bifidobacterium lactis Probio-M8 in the product for relieving asthma is more than or equal to 1 × 106CFU/g。
The product for relieving asthma also comprises a bean product, a dairy product or a fruit and vegetable product which is produced by using a leaven containing bifidobacterium lactis Probio-M8.
In an achievable mode, the adjuvant of the functional food for relieving asthma comprises special food for asthma and special food for the aged.
In one realizable approach, the functional pharmaceutical adjunct materials include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, tonicity adjusting agents, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integration agents, penetration enhancers, pH adjusting agents, buffers, plasticizers, surfactants, foaming agents, antifoaming agents, thickeners, encapsulation agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids, and release retardants.
In one achievable form, the asthma-relieving product further comprises an additive comprising microcrystalline cellulose, hydroxypropyl methylcellulose, and refined lecithin.
In one implementation, the asthma-relieving product further comprises a pharmaceutical product in a dosage form comprising granules, capsules, tablets, pills, or oral liquid.
The application fields comprise the clinical application field, the food field and the functional food field.
The application provides a bifidobacterium lactis Probio-M8 strain for relieving asthma and application thereof, wherein the bifidobacterium lactis Probio-M8 has the effect of relieving asthma, and is specifically represented as follows: significantly improve the clinical symptoms of asthma patients; the richness of Klebsiella pneumoniae of a patient is obviously reduced; the abundance of bifidobacteria in intestinal animals of patients is remarkably increased; significantly reducing the metabolism of aldosterone synthesis and secretion in the patient. Therefore, the bifidobacterium lactis Probio-M8 can improve the cell factors in the organism by regulating the intestinal flora, achieve good immune function, effectively relieve asthma symptoms and have great prospect in preparing products for relieving asthma. The remarkable functional characteristics of the bifidobacterium lactis Probio-M8 enable the bifidobacterium lactis to be widely applied to direct vat set starter cultures, probiotic solid beverages, foods, medicines and functional medicine auxiliary materials.
The test methods and conditions in the examples of the present invention are conventional methods unless otherwise specified.
Example (b): clinical trial of Bifidobacterium lactis Probio-M8 asthma population
Test method 1
Bifidobacterium lactis Probio-M8 is gram-positive bacterium, and the agar plate generates a convex milky colony with diameter of 1-2mm, complete edge and smooth surface. The cell shape is dumbbell shaped bacillus, two ends are regular, and a plurality of obvious nodes are arranged, and the bifidobacterium Probio-M8 is heterotypic fermentation.
36 volunteers, including 18 males and 18 females, were recruited between the ages of 28-61. 36 volunteers were randomly divided into placebo (20) and probiotic (16) groups for 90 days intervention. 16 indices closely related to respiratory diseases were examined on days 0, 30, 60 and 90, respectively, and stool and blood samples were collected. The influence of the bifidobacterium lactis Probio-M8 on adult asthma is comprehensively evaluated by combining the analysis results of clinical indexes, metabonomics, metagenomics and the like. See figure 1 for a specific experimental protocol.
2. Bifidobacterium lactis Probio-M8 for improving asthma clinical symptoms
Indexes closely related to respiratory diseases are detected on 0 day, 30 days, 60 days and 90 days of eating the bifidobacterium lactis Probio-M8 solid beverage respectively. Where ACT represents the asthma control test score, FeNO represents exhaled nitric oxide concentration values (normal values less than 25ppb for adults and less than 20ppb for children), and CaNO represents alveolar nitric oxide concentration values (normal values typically less than 5 ppb).
As can be seen from fig. 2, the ACT index continued to increase with the intervention of bifidobacterium lactis Probio-M8, which was significantly higher than 0 day (P ═ 0.019) at 90 days of treatment, indicating that bifidobacterium lactis Probio-M8 was effective in controlling asthma symptoms; as can be seen from fig. 3, FeNO decreased significantly at 30 days of treatment, the concentration of which was highly correlated with inflammation, a significant decrease in FeNO concentration indicating a significant improvement in airway inflammation in the patient; CaNO is associated with small airway inflammation, and the CaNO concentration is obviously reduced after 90 days of treatment by the bifidobacterium lactis Probio-M8, which shows that the degree of airway inflammation of patients after the treatment by the bifidobacterium lactis Probio-M8 is obviously lower than that of a placebo group. Wherein the abscissa of fig. 2 and 3 is the group and the ordinate is the number of days.
In conclusion, Bifidobacterium lactis Probio-M8 can improve clinical symptoms of asthma patients.
3. Effect of Bifidobacterium lactis Probio-M8 on flora structure of asthma patients
Extracting DNA of a fecal sample, sequentially carrying out random fragmentation, end repair and linker box connection on the DNA meeting the sequencing requirement to construct a library, and then sequencing the sample by utilizing Illumina GAIIx and HiSeq 2000 to analyze the influence of probiotics on functional genes and metabolic pathways of flora.
It can be seen from fig. 4 that the abundance of Klebsiella pneumoniae (Klebsiella pneumoniae) of patients is reduced after the bifidobacterium lactis Probio-M8 solid beverage is eaten, and thus it is inferred that the bifidobacterium lactis Probio-M8 can relieve asthma symptoms by reducing Klebsiella pneumoniae.
After intervention treatment with bifidobacterium lactis Probio-M8, the association network of the intestinal flora and the clinical index was changed compared with the placebo group. As can be seen from fig. 5, the bifidobacterium animalis of the probiotic group patients showed an increase in their abundance at different stages of administration, and the species correlated with multiple clinical indicators, indicating that the improvement in clinical symptoms may be associated with bifidobacteria.
In conclusion, the bifidobacterium lactis Probio-M8 can be competitively colonized with harmful bacteria, reduce the content of the harmful bacteria, increase the abundance of beneficial bacteria and influence the structure of the flora in the lung, thereby improving the lung function and relieving the asthma symptom.
4. Effect of Bifidobacterium lactis Probio-M8 on metabolic function of asthmatic patients
The serum and the excrement samples are pre-treated, and the whole spectrum of the serum and the excrement samples is measured in a non-targeting way through an LC-MS technology so as to determine the metabolic difference substances among different treatment groups.
Compared with the placebo group, the metabolic functions of asthma patients are different after the intervention treatment of the bifidobacterium lactis Probio-M8. In the probiotic group, the aldosterone synthesis and secretory metabolic pathways of asthma patients are reduced, indicating that bifidobacterium lactis Probio-M8 may participate in asthma airway remodeling by affecting aldosterone metabolism, and relieve pulmonary fibrosis, thereby relieving asthma symptoms, as shown in figure 6.
Human body tests show that the bifidobacterium lactis Probio-M8 has obvious effect of relieving asthma symptoms.
Other embodiments of the present application will be apparent to those skilled in the art from consideration of the specification and practice of the application disclosed herein. It should be noted that the above-mentioned embodiments illustrate rather than limit the invention, and that, although the invention has been described with reference to embodiments thereof, it will be understood by those skilled in the art that other changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
The embodiments provided in the present application are only a few examples of the general concept of the present application, and do not limit the scope of the present application. Any other embodiments extended according to the scheme of the present application without inventive efforts will be within the scope of protection of the present application for a person skilled in the art.
Claims (8)
1. A Bifidobacterium lactis Probio-M8 for relieving asthma is characterized in that the microorganism preservation number is CGMCC No. 18610.
2. Use of bifidobacterium lactis Probio-M8 as claimed in claim 1 in the manufacture of a product for relieving asthma.
3. Use according to claim 2, comprising the bifidobacterium lactis Probio-M8 for the preparation of a functional health product.
4. The use of claim 3, wherein the functional health product comprises a ready-to-use starter, a probiotic solid beverage, a tabletted candy and a functional pharmaceutical auxiliary material.
5. The use according to claim 2 or 3, wherein the viable count of the Bifidobacterium lactis Probio-M8 in the product is not less than 1 × 106CFU/g。
6. A product for relieving asthma, which contains bifidobacterium lactis Probio-M8 as claimed in claim 1, and which comprises a food product and a health food.
7. The product for relieving asthma according to claim 6, wherein the viable count of Bifidobacterium lactis Probio-M8 in the product is not less than 1 × 106CFU/g。
8. The product for relieving asthma according to claim 6 or 7, wherein the product further comprises a soy product, a dairy product or a fruit and vegetable product produced by using a starter culture containing Bifidobacterium lactis Probio-M8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010460612.4A CN111560335B (en) | 2020-05-26 | 2020-05-26 | Bifidobacterium lactis for relieving asthma and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010460612.4A CN111560335B (en) | 2020-05-26 | 2020-05-26 | Bifidobacterium lactis for relieving asthma and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111560335A true CN111560335A (en) | 2020-08-21 |
| CN111560335B CN111560335B (en) | 2022-09-23 |
Family
ID=72072466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010460612.4A Active CN111560335B (en) | 2020-05-26 | 2020-05-26 | Bifidobacterium lactis for relieving asthma and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111560335B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116083323A (en) * | 2023-03-16 | 2023-05-09 | 威凯海思(山东)生物工程有限公司 | Bifidobacterium lactis HC2786 capable of relieving anaphylactic reaction, and product and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103898018A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | High-density culture method of bifidobacterium lactis and preparation method of freeze-dried powder of bifidobacterium lactis |
| CN104168905A (en) * | 2011-06-10 | 2014-11-26 | 杜邦营养生物科学有限公司 | Treatment of respiratory tract illness with bifidobacterium lactis bl-04 |
| US20200054691A1 (en) * | 2018-08-16 | 2020-02-20 | Grape King Bio Ltd. | Bifidobacterium lactis gkk2, a composition comprising thereof and its use for improving allergic asthma |
-
2020
- 2020-05-26 CN CN202010460612.4A patent/CN111560335B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104168905A (en) * | 2011-06-10 | 2014-11-26 | 杜邦营养生物科学有限公司 | Treatment of respiratory tract illness with bifidobacterium lactis bl-04 |
| CN103898018A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | High-density culture method of bifidobacterium lactis and preparation method of freeze-dried powder of bifidobacterium lactis |
| US20200054691A1 (en) * | 2018-08-16 | 2020-02-20 | Grape King Bio Ltd. | Bifidobacterium lactis gkk2, a composition comprising thereof and its use for improving allergic asthma |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116083323A (en) * | 2023-03-16 | 2023-05-09 | 威凯海思(山东)生物工程有限公司 | Bifidobacterium lactis HC2786 capable of relieving anaphylactic reaction, and product and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111560335B (en) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10286026B2 (en) | Probiotic fermented cereal compositions and methods for treatment of gastrointestinal diseases caused by pro-inflammatory bacteria | |
| CN100421676C (en) | Lactic acid producing bacteria and lung function | |
| CN102115721B (en) | Lactobacillus isolates with anti-inflammatory activity and uses thereof | |
| US20220072067A1 (en) | Pediococcus acidilactici CCFM6432 for Alleviating Depression, Food Fermented Thereby and Application Thereof | |
| TWI759126B (en) | Anti-inflammation and treatment of inflammatory disorders with liquid culture of lactic acid bacteria strains | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN116987608B (en) | Probiotic composition and application thereof in preparation of depression-complicated diarrhea-type irritable bowel syndrome medicines | |
| CN114432346A (en) | Composite probiotic composition for treating hyperuricemia and gout and preparation method and application thereof | |
| CN118497080B (en) | Fermented lactobacillus mucilaginosus and application thereof in preparation of ulcerative colitis relieving products | |
| CN103550258B (en) | Use of Lactic Acid Bacteria Strains to Modulate Immune Response | |
| CN115820498A (en) | Lactobacillus plantarum YJ2406 and application thereof | |
| WO2018112741A1 (en) | Lactobacillus acidophilus, culture method therefor and application thereof | |
| WO2018112739A1 (en) | Bifidobacterium pseudocatenulatum, culture method therefor and application thereof | |
| JP2023519233A (en) | Microorganisms for improving liver function or suppressing fat accumulation, and uses thereof | |
| TWI711458B (en) | Plant ferment, preparation method thereof and use thereof for stomach health care | |
| CN117004503A (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| WO2018112740A1 (en) | Lactobacillus gasseri, culture method therefor and application thereof | |
| CN113797232B (en) | Composition with insulin resistance relieving function and application thereof | |
| CN111560335B (en) | Bifidobacterium lactis for relieving asthma and application thereof | |
| CN114686405A (en) | Bifidobacterium bifidum capable of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| CN119193391A (en) | Lactobacillus plantarum Lp116 with blood sugar lowering ability and its application, product and method | |
| Zuo et al. | Effect of fermented Rosa roxburghii tratt fruit juice on gut microbiota in a dextran sulfate sodium (DSS)-induced colitis mouse model | |
| CN117159598A (en) | Application of lactobacillus plantarum Lp18 in preparation of immunity-enhancing medicines or health-care foods and products | |
| TWI429444B (en) | Novel lactobacillus strains and their uses for modulating immune response | |
| CN111296842A (en) | Probiotic composition with anti-allergy effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |